[go: up one dir, main page]

WO2009054653A3 - Isoindolones with high binding affinity to beta-amyloid aggregates and fibrils, and its use and preparation method - Google Patents

Isoindolones with high binding affinity to beta-amyloid aggregates and fibrils, and its use and preparation method Download PDF

Info

Publication number
WO2009054653A3
WO2009054653A3 PCT/KR2008/006183 KR2008006183W WO2009054653A3 WO 2009054653 A3 WO2009054653 A3 WO 2009054653A3 KR 2008006183 W KR2008006183 W KR 2008006183W WO 2009054653 A3 WO2009054653 A3 WO 2009054653A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta
binding affinity
high binding
fibrils
isoindolones
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2008/006183
Other languages
French (fr)
Other versions
WO2009054653A2 (en
Inventor
Ji-Hoon Lee
Dong-Jin Kim
Woong-Seo Park
Yong-Goo Kang
Kyung-Ho Yoo
Hyu-Ji Lee
Dae-Hyuk Moon
Seung-Jun Oh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Science and Technology KIST
Original Assignee
Korea Institute of Science and Technology KIST
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Science and Technology KIST filed Critical Korea Institute of Science and Technology KIST
Publication of WO2009054653A2 publication Critical patent/WO2009054653A2/en
Publication of WO2009054653A3 publication Critical patent/WO2009054653A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to isoindolone compounds having high binding affinity to beta-amyloid fibrils, thereby being useful for an early diagnosis of degenerative cerebral diseases including dementia, and prevention and treatment of such diseases, its use and a method for preparing the same.
PCT/KR2008/006183 2007-10-26 2008-10-20 Isoindolones with high binding affinity to beta-amyloid aggregates and fibrils, and its use and preparation method Ceased WO2009054653A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2007-0108420 2007-10-26
KR1020070108420A KR101068835B1 (en) 2007-10-26 2007-10-26 Isoindoleone compounds having excellent binding affinity to beta-amyloid aggregates and fibrils and methods for their preparation

Publications (2)

Publication Number Publication Date
WO2009054653A2 WO2009054653A2 (en) 2009-04-30
WO2009054653A3 true WO2009054653A3 (en) 2009-06-11

Family

ID=40580231

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/006183 Ceased WO2009054653A2 (en) 2007-10-26 2008-10-20 Isoindolones with high binding affinity to beta-amyloid aggregates and fibrils, and its use and preparation method

Country Status (2)

Country Link
KR (1) KR101068835B1 (en)
WO (1) WO2009054653A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
AU2009220244B2 (en) 2008-02-29 2014-10-09 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
WO2010104324A2 (en) * 2009-03-10 2010-09-16 한국과학기술연구원 Halogenated isoindole compounds with superior binding affinity to beta-amyloid aggregates and fibrils, method for preparing same, and use thereof
EP3323810B1 (en) 2010-02-08 2022-01-05 Lantheus Medical Imaging, Inc. Automated reaction system, cassette and apparatus for synthesizing imaging agents
BR122019017259B1 (en) 2011-09-09 2022-05-10 Lantheus Medical Imaging, Inc Compounds useful as imaging agents, compositions comprising them, methods, and use of imaging agents
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
EP3452447A4 (en) * 2016-05-03 2019-12-18 The Regents of The University of California IRES-MEDIATED PROTEIN SYNTHESIS INHIBITORS
CN110498759A (en) * 2019-09-12 2019-11-26 天津瑞岭化工有限公司 The synthetic method of isoindoline ketone compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6365753B1 (en) * 1998-06-17 2002-04-02 Mitsubishi Chemical Corporation Phthalimides and herbicide containing the same as active component
US6429212B1 (en) * 1996-08-16 2002-08-06 Ishihara Sangyo Kaisha Ltd. Medicinal composition
WO2002096078A1 (en) * 2001-05-24 2002-11-28 Qualcomm Incorporated Apparatus and method for reducing power consumption in a mobile unit
WO2005021532A1 (en) * 2003-08-25 2005-03-10 Amgen Inc Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002257195A1 (en) * 2001-04-23 2002-11-05 University Of Virginia Patent Foundation Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
DE10337074A1 (en) 2003-08-12 2005-03-17 Keyneurotek Ag Use of the inhibitors of enzymes with activities of aminopeptidase N and / or dipeptidyl peptidase IV and pharmaceutical preparations thereof for the therapy and prevention of chronic neurodegenerative diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429212B1 (en) * 1996-08-16 2002-08-06 Ishihara Sangyo Kaisha Ltd. Medicinal composition
US6365753B1 (en) * 1998-06-17 2002-04-02 Mitsubishi Chemical Corporation Phthalimides and herbicide containing the same as active component
WO2002096078A1 (en) * 2001-05-24 2002-11-28 Qualcomm Incorporated Apparatus and method for reducing power consumption in a mobile unit
WO2005021532A1 (en) * 2003-08-25 2005-03-10 Amgen Inc Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAGNUCCI A.H. ET AL.: "Alzheimer's disease and angiogenesis", THE LANCET, vol. 361, 2003, pages 605 - 608 *

Also Published As

Publication number Publication date
WO2009054653A2 (en) 2009-04-30
KR101068835B1 (en) 2011-09-30
KR20090042579A (en) 2009-04-30

Similar Documents

Publication Publication Date Title
WO2009054653A3 (en) Isoindolones with high binding affinity to beta-amyloid aggregates and fibrils, and its use and preparation method
WO2010142423A3 (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
WO2008150946A8 (en) HUMANIZED ANTIBODIES WHICH BIND TO Aβ (1-42) GLOBULOMER AND USES THEREOF
DK3872058T3 (en) Process for the preparation of 2,3,3,3 tetrahydrofluoropropene
WO2008070692A8 (en) Bicyclic compounds and use as antidiabetics
WO2008097461A3 (en) Hepcidin and hepcidin antibodies
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
SI2346864T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
WO2007137071A3 (en) Compositions of r(+) and s(-) pramipexole and methods of using the same
WO2008112192A3 (en) Epha3 antibodies for the treatment of solid tumors
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2008153937A3 (en) Novel 1- heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
IL183965A0 (en) Novel process for the preparation of substituted indoles
WO2009053446A3 (en) Pregabalin intermediates and process for preparing them and pregabalin
WO2007132354A3 (en) Process for preparing voriconazole, new polymorphic form of intermediate thereof, and uses thereof
WO2009056707A3 (en) Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
WO2006000547A3 (en) Method for producing an iron sulfate-based phosphate adsorbent
WO2007131907A3 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
WO2008137134A3 (en) Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
WO2007103584A3 (en) Polyamides for treating human papilloma virus
WO2006122123A3 (en) Methods of alleviating disorders and their associated pain
WO2010104324A3 (en) Halogenated isoindole compounds with superior binding affinity to beta-amyloid aggregates and fibrils, method for preparing same, and use thereof
WO2008041176A3 (en) Process for the preparation of form i and form ii of ritonavir

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08841533

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 12.08.2010)

122 Ep: pct application non-entry in european phase

Ref document number: 08841533

Country of ref document: EP

Kind code of ref document: A2